We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 78

EU daily updates: foodconsumer policypharmaceuticals - 19112007

  • Hogan Lovells
  • -
  • European Union
  • -
  • November 19 2007

Commission Decision of 8 November 2007 amending Decision 2007102EC adopting the work plan for 2007 for implementation of the programme of Community action in the field of public health (2003 to 2008), including the annual work programme for grants

Commission supplements the health and nutrition claims Regulation by adopting rules on generic descriptors

  • Hogan Lovells
  • -
  • European Union
  • -
  • October 16 2013

On 20 September 2013, the European Commission adopted implementing rules for so-called generic descriptors under Article 1(4) of the Regulation (EC

EU daily update: food consumer policy pharmaceuticals - 171007

  • Hogan Lovells
  • -
  • European Union
  • -
  • October 17 2007

According to the draft health services directive expected to be unveiled on November 20, 2007, patients would be able to travel abroad for treatment based on clinical needs rather than waiting time and would be reimbursed up to the amount provided by their domestic system

European Commission fines for delaying market entry of generic medicines

  • Hogan Lovells
  • -
  • European Union
  • -
  • June 20 2013

The European Commission yesterday imposed a fine of Euro 93.8 million on Danish pharmaceutical company Lundbeck and fines totalling Euro 52.2 million

European Commission launches monitoring of patent settlement agreements

  • Hogan Lovells
  • -
  • European Union
  • -
  • March 11 2010

While the pharmaceutical sector might have felt some relief that the Final Report from the Pharmaceutical Sector Inquiry (Sector Inquiry) was more balanced than its Interim Report, the European Commission (Commission) is maintaining its focus on competition in this sector

Updated EMA guidance on maintenance of information requirements

  • Hogan Lovells
  • -
  • European Union
  • -
  • February 17 2014

The European Medicines Agency ("EMA") has updated its guidance documents to reflect new European Union ("EU") requirements which require Marketing

EC closes two pharma investigations, but national authorities continue antitrust scrutiny

  • Hogan Lovells
  • -
  • European Union
  • -
  • June 12 2012

In early March, the EC announced in quick succession the closure of investigations into alleged anti-competitive practices by AstraZeneca and GlaxoSmithKline, among others, that it considered may have delayed the entry of generic drugs onto the market

The Court of Justice of the European Union declares that the prohibition in the Community Code on provision of inducements to healthcare professionals to prescribe medicinal products does not apply to national health authority policies

  • Hogan Lovells
  • -
  • European Union
  • -
  • April 29 2010

The Court held that the provisions of the European Union (hereafter the "EU") legislation imposing restrictions on the promotion and advertising of medicinal products apply only to pharmaceutical companies and independent third parties

Supplementary protection certificates: can a negative lead to something positive?

  • Hogan Lovells
  • -
  • European Union
  • -
  • July 21 2011

Ever since the introduction of the Pediatric Regulation the question of whether it is permissible to grant a negative or zero term Supplementary Protection Certificate (SPC) has been controversial, with a range of inconsistent decisions across the EU

European Commission signals new approach to relevant product market definition in pharmaceutical merger cases

  • Hogan Lovells
  • -
  • European Union
  • -
  • March 29 2009

On February 4, 2009, the European Commission approved Sanofi-Aventis’s acquisition of Czech generics pharmaceutical manufacturer Zentiva